Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 5,000 shares, an increase of 47.1% from the May 31st total of 3,400 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is presently 1.2 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Genenta Science in a research note on Monday, May 13th.
View Our Latest Report on Genenta Science
Genenta Science Price Performance
Genenta Science Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Read More
- Five stocks we like better than Genenta Science
- What Are the FAANG Stocks and Are They Good Investments?
- Applied Digital Boosts Stock with Cutting-Edge AI Data Centers
- How to Effectively Use the MarketBeat Ratings Screener
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- How to Invest in Gold: A Complete Guide
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.